ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis
USA - NASDAQ:ADXN - US00654J2069 - ADR
9.9213 USD
+0.32 (+3.35%)
Taking everything into account, ADXN scores 1 out of 10 in our fundamental rating. ADXN was compared to 192 industry peers in the Pharmaceuticals industry. ADXN may be in some trouble as it scores bad on both profitability and health. ADXN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ADXN has reported negative net income.
In the past year ADXN has reported a negative cash flow from operations.
In the past 5 years ADXN reported 4 times negative net income.
ADXN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ADXN has a Return On Assets of -66.46%. This is in the lower half of the industry: ADXN underperforms 65.63% of its industry peers.
With a Return On Equity value of -78.38%, ADXN perfoms like the industry average, outperforming 45.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.46% | ||
| ROE | -78.38% | ||
| ROIC | N/A |
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADXN has been increased compared to 1 year ago.
The number of shares outstanding for ADXN has been increased compared to 5 years ago.
ADXN has a better debt/assets ratio than last year.
2.2 Solvency
ADXN has an Altman-Z score of -50.28. This is a bad value and indicates that ADXN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ADXN (-50.28) is worse than 91.15% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ADXN is not too dependend on debt financing.
ADXN has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -50.28 |
ROIC/WACCN/A
WACC4.94%
2.3 Liquidity
ADXN has a Current Ratio of 2.31. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.31, ADXN is in line with its industry, outperforming 41.67% of the companies in the same industry.
A Quick Ratio of 2.31 indicates that ADXN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.31, ADXN perfoms like the industry average, outperforming 47.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.31 | ||
| Quick Ratio | 2.31 |
3. Growth
3.1 Past
ADXN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -276.06%.
The Revenue for ADXN has decreased by -34.65% in the past year. This is quite bad
The Revenue for ADXN have been decreasing by -32.07% on average. This is quite bad
EPS 1Y (TTM)-276.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-115%
Revenue 1Y (TTM)-34.65%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-68.43%
3.2 Future
ADXN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.95% yearly.
ADXN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.95%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADXN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADXN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ADXN's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
5. Dividend
5.1 Amount
No dividends for ADXN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ADXN (10/27/2025, 8:02:12 PM)
9.9213
+0.32 (+3.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.32%
Inst Owner Change0%
Ins Owners7.07%
Ins Owner ChangeN/A
Market Cap10.60M
Revenue(TTM)564.10K
Net Income(TTM)-5653200
Analysts40
Price Target7.61 (-23.3%)
Short Float %1.31%
Short Ratio0.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.21%
EPS NY rev (3m)-19.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.86
EYN/A
EPS(NY)-4.82
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0.66
BVpS8.47
TBVpS8.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.46% | ||
| ROE | -78.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.31 | ||
| Quick Ratio | 2.31 | ||
| Altman-Z | -50.28 |
F-Score2
WACC4.94%
ROIC/WACCN/A
Cap/Depr(3y)0.97%
Cap/Depr(5y)5.54%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-276.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-115%
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.95%
Revenue 1Y (TTM)-34.65%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-68.43%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y67.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.67%
EBIT Next 3Y5.45%
EBIT Next 5Y5.93%
FCF growth 1Y86.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.76%
OCF growth 3YN/A
OCF growth 5YN/A
ADDEX THERAPEUTICS LTD / ADXN FAQ
What is the fundamental rating for ADXN stock?
ChartMill assigns a fundamental rating of 1 / 10 to ADXN.
Can you provide the valuation status for ADDEX THERAPEUTICS LTD?
ChartMill assigns a valuation rating of 0 / 10 to ADDEX THERAPEUTICS LTD (ADXN). This can be considered as Overvalued.
What is the profitability of ADXN stock?
ADDEX THERAPEUTICS LTD (ADXN) has a profitability rating of 0 / 10.
Can you provide the financial health for ADXN stock?
The financial health rating of ADDEX THERAPEUTICS LTD (ADXN) is 3 / 10.
Can you provide the expected EPS growth for ADXN stock?
The Earnings per Share (EPS) of ADDEX THERAPEUTICS LTD (ADXN) is expected to decline by -1500% in the next year.